TROP-2 is a cell surface glycoprotein that is frequently overexpressed in multiple carcinomas

BAT8008 is a novel Trop2-targered antibody-drug conjugate (ADC) composed of a fully-humanized anti-Trop2 monoclonal antibody covalently linked to topoisomerase I inhibitor payload (Exatecan) via a cleavable maleimide tetrapeptide-based cleavable linker


Preclinical studies of BAT8008 showed a favorable safety profile and potent antitumor activity.

This is a first-in-human, dose-escalation and expansion study in patients with advanced/metastatic solid tumors

Patients are not selected for Trop2 expression except for some certain GI tumor types. The association of trop2 expression level and antitumor response will be assessed.

Part 1- Dose Escalation

Part 2- Dose Expansion



As of April 20, 2025, 194 patients (pts) were enrolled with doses ranging from 0.8 to 2.7mg/kg.

Baseline characteristics are included in .

All patients had received at least one line of systemic chemotherapy. Median prior lines of Tx were 2(range, 1-7).

The reported NSCLC cohort is all driver gene wild-type non-squamous NSCLC.

The reported Her2- BC cohort includes TNBC and HR+ BC.

Objective responses were also observed in other solid tumor types.

BAT8008 was well tolerated and all AEs were manageable.

Promising clinical efficacy was observed in pretreated Her2- BC NSCLC ESCC and CC patients at 2.4mg/kg dose level.

Expansion study is ongoing at doses of 2.1mg/kg and 2.4mg/kg to evaluate the efficacy and safety of BAT8008 in several types of tumors.

The exploratory study of BAT8008 in combination with BAT1308 (PD-1 monoclonal antibody) is also underway in patients with ≥1st line various solid tumors.